Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Polynovo ( (AU:PNV) ) just unveiled an update.
Polynovo Limited announced a change in the director’s interest notice, indicating that Director David Williams has acquired an additional 31,000 ordinary shares through Moggs Creek Pty Ltd, a related entity. This acquisition, completed via an on-market trade, reflects a continued investment in the company, potentially signaling confidence in Polynovo’s strategic direction and market position.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
More about Polynovo
Polynovo Limited operates in the medical technology industry, primarily focusing on the development and commercialization of innovative medical devices. The company is known for its NovoSorb technology, which is used in a range of products aimed at improving wound care and tissue repair.
Average Trading Volume: 2,677,259
Technical Sentiment Signal: Sell
Current Market Cap: A$967.2M
For a thorough assessment of PNV stock, go to TipRanks’ Stock Analysis page.